|
Areas in which personalized approaches are particularly promising include oncology, cardiovascular diseases, neurodegenerative diseases, psychiatric disorders, diabetes and obesity, arthritis, pain, and Alzheimer’s disease. In all of these fields, and others, a personalized molecular medicine approach is expected to lead to better health outcomes, improved treatments, and a reduction in toxicity due to variable or adverse drug responses. Cancer patients, for example, would be screened to identify those for whom chemotherapy would be ineffective. In addition to saving on the costs of expensive drug treatments, the government hopes this personalized treatment would prevent a great deal of suffering, while identifying and initiating earlier treatments that could be more effective.
The funding will be divided into: Genome Canada, $40 million; the Canadian Institute of Health Research, $22.5 million; and the Cancer Stem Cell Consortium, $5 million. The funds will be given to the three research agencies once they have obtained matching funding that is least equal to that provided. Matching funding is typically derived from provincial, academic, private sector or international sources.
In a televised interview on Jan. 31st with CTV’s Sandie Rinaldo, Minister Aglukkaq said that she hopes to see results in three to four years.
Source: Canadian Institutes of Health Research, cihr-irsc.gc.ca
|